Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older

Phase 1

Withdrawn

Conditions: Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed Philadelphia Chromosome Negative
Aged 60 Years or Older

Interventions: Drug: Erwinia Chrysanthemi asparaginase

First Posted Date: 2016-01-06

Last Posted Date: 2017-06-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02647190

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT)

First Posted Date: 2015-12-31

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT02643498

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent and follow-up only), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Consent and follow-up only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States

and more 4 locations

Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients

Phase 1

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Enzalutamide
Drug: Enzalutamide with Sorafenib

First Posted Date: 2015-12-30

Last Posted Date: 2021-03-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 28

Registration Number: NCT02642913

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 2 locations

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Phase 1

Withdrawn

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Pemetrexed/Cisplatin
Radiation: Pleural Intensity Modulated Radiation Therapy
Device: MRI

First Posted Date: 2015-12-24

Last Posted Date: 2016-12-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02639767

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Untreated

Interventions: Drug: Lenalidomide
Drug: R-CHOP
Drug: high-dose cytarabine (HIDAC)

First Posted Date: 2015-12-17

Last Posted Date: 2023-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT02633137

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Active, not recruiting

Conditions: B-cell Non-Hodgkin Lymphoma
Aggressive

Interventions: Other: collected at pre-treatment tumor biopsy
Other: Peripheral blood tests
Device: PET/CT

First Posted Date: 2015-12-17

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 501

Registration Number: NCT02633111

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 8 locations

Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers

Withdrawn

Conditions: Oropharynx Cancers

Interventions: Other: blood draw
Behavioral: study questionnaire
Other: cardiopulmonary exercise testing (CPET)
Other: DXA (dual-energy x-ray absorptiometry) scan

First Posted Date: 2015-12-11

Last Posted Date: 2018-01-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT02628912

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Completed

Conditions: HER2-Positive Breast Cancer Survivors
Trastuzumab Cardiotoxicity

Interventions: Device: 2D Echocardiogram
Device: Cardiopulmonary exercise testing and post-CPET cardiac function

First Posted Date: 2015-11-25

Last Posted Date: 2024-04-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 58

Registration Number: NCT02615054

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

Not Applicable

Completed

Conditions: Neuroendocrine Tumors

Interventions: Device: PET/CT Imaging
Radiation: 68Ga-DOTA-JR11
Radiation: 177Lu-DOTA-JR11

First Posted Date: 2015-11-20

Last Posted Date: 2022-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT02609737

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement

Completed

Conditions: Histiocytic Disorders
Erdheim-Chester Disease
Langerhans Cell Histiocytosis

Interventions: Radiation: F-choline PET Scan
Device: FDG-PET
Procedure: biopsy

First Posted Date: 2015-11-20

Last Posted Date: 2018-08-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3

Registration Number: NCT02608619

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy